soliqua glp 1 100/33 Sanofi gets approval to sell

Originally developed to help manage type 2 diabetes, these drugs are now widely prescribed for weight loss due to their profound appetite-suppressing effects

Blood Sugar Control Supports overall metabolic health, especially for those with insulin resistance

In the SURMOUNT-1 trial, tirzepatide produced average weight reductions of 15.0%, 19.5%, and 20.9% at studied doses compared with 3.1% with placebo over 72 weeks

Significant results are typically observed after 12 to 16 weeks, with continued improvements over the course of the treatment

However, its important to note that not everyone is a suitable candidate for this treatment

2010;298:E634E643